Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 DDI Study of Abrocitinib with Fluvoxamine or Fluconazole in Healthy Subjects
NCT03634345Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abrocitinib in atopic dermatitis (AD) (2 cohorts), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours and Area Under the Curve From Time Zero to Extrapolated Infinite Time at 72 hours. Started Sep 2018; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03634345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634345.